# A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease

> **NCT02353598** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 77 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Crenezumab dose level 1
- **DRUG:** Crenezumab dose level 2
- **DRUG:** Crenezumb dose level 3
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02353598
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-26
- **Primary completion:** 2016-11-30
- **Final completion:** 2019-03-26
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2019-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02353598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02353598, "A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02353598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*